Clinical evidence for cannabis in cancer care was limited but growing
Clinical evidence for cannabis use in cancer patients was only partial for symptom management (pain, nausea, appetite loss), while laboratory evidence of anti-cancer effects had no clinical research support.
Quick Facts
What This Study Found
This review assessed the evidence for cannabis use by oncology patients. The authors found that clinical cannabis use in cancer patients had been rising significantly in several countries, driven primarily by public demand rather than scientific evidence.
The clinical evidence for symptom management was described as partial: cannabis showed some benefit for cancer-related pain, nausea and vomiting, and appetite loss, but the evidence was not considered robust. Recent data from THC/CBD combination studies provided the first clinical indication of cancer-related pain relief.
Laboratory studies demonstrated anti-cancer effects of cannabis components, but no clinical research had been conducted to test these effects in human cancer patients. The authors noted that the difficulty of performing research on non-medicinal botanical products had limited proper study of cannabis extract despite strong public interest.
Key Numbers
No specific trial statistics were reported. The review referenced recent THC/CBD combination data as the first clinical pain relief evidence. Anti-cancer effects were limited to laboratory findings with no clinical studies.
How They Did This
Narrative review of published literature on cannabis chemistry, potential anti-cancer effects, and clinical evidence for symptom management in oncology patients.
Why This Research Matters
Cancer patients frequently turn to cannabis for symptom management, often based on anecdotal evidence or media reports. This review provided oncologists and pharmacists with an evidence-based assessment of what was actually supported by clinical data versus what remained speculative.
The Bigger Picture
The gap between laboratory anti-cancer findings and the absence of clinical cancer treatment research highlights a broader challenge in cannabinoid medicine. Strong preclinical signals do not automatically translate to effective treatments, and the regulatory complexity of cannabis research has slowed the clinical trials needed to close this evidence gap.
What This Study Doesn't Tell Us
Narrative review without systematic methodology. The evidence landscape was rapidly changing at the time of publication. Cannabis chemistry complexity and product variability make standardized research challenging. Smoking as a delivery route carries its own cancer risk concerns.
Questions This Raises
- ?Have clinical trials of cannabinoids as anti-cancer agents been conducted since this review?
- ?Does cannabis use affect cancer treatment efficacy or drug interactions?
- ?What is the optimal cannabinoid formulation for cancer symptom management?
Trust & Context
- Key Stat:
- Lab anti-cancer effects existed but zero clinical cancer treatment trials had been done
- Evidence Grade:
- Narrative review summarizing a mixed evidence base of partial clinical support for symptoms and preclinical-only anti-cancer data.
- Study Age:
- Published in 2014. The evidence base for cannabinoids in oncology has continued to evolve.
- Original Title:
- Is the clinical use of cannabis by oncology patients advisable?
- Published In:
- Current medicinal chemistry, 21(17), 1923-30 (2014)
- Authors:
- Bar-Sela, Gil(5), Avisar, Adva, Batash, Ron, Schaffer, Moshe
- Database ID:
- RTHC-00763
Evidence Hierarchy
Summarizes existing research on a topic.
What do these levels mean? →Frequently Asked Questions
Can cannabis treat cancer?
As of this 2014 review, laboratory studies showed anti-cancer effects from cannabis components, but no clinical trials had tested whether these effects work in human cancer patients. The distinction between lab findings and clinical evidence is important.
Does cannabis help with cancer symptoms?
The clinical evidence for pain, nausea, and appetite loss was described as partial. THC/CBD combinations showed the most promising early clinical data for cancer-related pain relief.
Read More on RethinkTHC
- CBD-oil-quality-guide
- anxiety-medication-after-quitting-weed
- cannabis-chemotherapy-nausea
- cannabis-chronic-pain-research
- cannabis-epilepsy-CBD-Epidiolex
- cbd-anxiety-research-evidence
- cbd-for-weed-withdrawal
- cbd-vs-thc-difference
- medical-benefits-of-cannabis
- quitting-weed-before-surgery
- quitting-weed-medication-interactions
- quitting-weed-pregnancy
- quitting-weed-pregnant
- seniors-older-adults-cannabis-risks-medications
- weed-breastfeeding-THC-breast-milk
Cite This Study
https://rethinkthc.com/research/RTHC-00763APA
Bar-Sela, Gil; Avisar, Adva; Batash, Ron; Schaffer, Moshe. (2014). Is the clinical use of cannabis by oncology patients advisable?. Current medicinal chemistry, 21(17), 1923-30.
MLA
Bar-Sela, Gil, et al. "Is the clinical use of cannabis by oncology patients advisable?." Current medicinal chemistry, 2014.
RethinkTHC
RethinkTHC Research Database. "Is the clinical use of cannabis by oncology patients advisab..." RTHC-00763. Retrieved from https://rethinkthc.com/research/bar-sela-2014-is-the-clinical-use
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.